预约演示
更新于：2025-03-30
Edaravone/Dexborneol
依达拉奉右莰醇
更新于：2025-03-30
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2020-07-29), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、特殊审批 (中国)、突破性疗法 (中国) |
登录后查看时间轴
结构/序列
分子式C10H18O |
InChIKeyDTGKSKDOIYIVQL-QXFUBDJGSA-N |
CAS号464-45-9 |
查看全部结构式(2)
关联
42
项与 依达拉奉右莰醇 相关的临床试验NCT06674460
Treatment of Acute Ischemic Stroke with Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease: a Randomized, Double-Blind, Placebo-Controlled Study
ChiCTR2400092364
Clinical efficacy of edaravone dexborneol combined with hyperbaric oxygen therapy (HBOT) in the treatment of acute ischemic stroke based on real-world data - A study on clinical efficacy of edaravone dexborneol combined with hyperbaric oxygen therapy (HBOT) in the treatment of acute ischemic stroke
NCT06645522
Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
100 项与 依达拉奉右莰醇 相关的临床结果
登录后查看更多信息
100 项与 依达拉奉右莰醇 相关的转化医学
登录后查看更多信息
100 项与 依达拉奉右莰醇 相关的专利（医药）
登录后查看更多信息
61
项与 依达拉奉右莰醇 相关的文献（医药）2025-05-01PHYTOMEDICINE
Edaravone dexborneol exerts anti-epileptic effects on rodent temporal lobe epilepsy by promoting NMDAR deactivation and inhibiting oxidative stress
Article
作者: Li, Yiqian ; Pan, Lechen ; Xu, Huiqin ; Xie, Chenglong ; Huang, Wenting ; Wang, Xinshi ; Li, Yuqian ; Qiu, Wanhua ; Chen, Roumeng ; Lin, Li ; Xu, Yuchen ; Li, Peijun ; Guo, Ang ; Tan, Tao
BACKGROUND:
Disease-modifying treatments with anti-epileptic effects are currently unavailable and urgently required for temporal lobe epilepsy (TLE). Combined therapy targeting multiple mechanisms may offer a promising anti-epileptic strategy, given the complex processes underlying epileptogenesis.
PURPOSE:
This study evaluates the effects of Edaravone Dexbroneol, a combination of Edaravone and Dexborneol in 4:1, on rat and mouse TLE models and an in vitro epileptiform activity model.
METHODS:
The Pilocarpine-induced rat TLE model and the Kainic acid-induced mouse TLE model were used to assess the in vivo effect of Edaravone and/or Dexbornel. Primary neurons were utilized to evaluate the in vitro effect of drugs using calcium imaging, electrophysiological and biochemical analyses, as well as RNA sequencing.
RESULTS:
Treatment of Edaravone Dexbornel during the latent period significantly alleviated epileptic seizures in rodents, mitigated cognitive impairment, and inhibited neuronal loss and astrocytic activation. In vitro, Edaravone Dexborneol inhibited the action potentials and protected primary hippocampal neurons from Mg2+-free-induced neurite injury. All these effects were significantly more pronounced in the group treated with the Edaravone Dexborneol mixture compared to either drug used individually. Furthermore, Edaravone can significantly inhibit Mg2+-free-induced calcium oscillations in primary neurons, probably by promoting the deactivation of NMDA receptors. RNA sequencing and RT-PCR analysis revealed that synergetic regulation of lipid metabolism, oxidative stress, apoptosis, and calcium signaling probably underlay the neuroprotective effect of Edaravone Dexbornel on epileptic neurons.
CONCLUSION:
Edaravone Dexborneol exhibits antiepileptic effects and may fill the gap in disease-modifying treatments for TLE.
2024-12-01Stroke and vascular neurology
Rationale and design of Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol II (TASTE-2): a multicentre randomised controlled trial
Article
作者: Dong, Qiang ; Wang, Yongjun ; Gu, Hong-Qiu ; Yang, Yi ; Xu, Anding ; Wang, Feng ; Wang, Ning ; Wang, Chunjuan
Background:
Edaravone dexborneol is believed to be a novel cytoprotective drug, demonstrating a synergistic combination of antioxidative and anti-inflammatory properties in animal models. The Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol (TASTE) trial demonstrated its superior efficacy over edaravone alone for acute ischaemic stroke (AIS) patients. However, its efficacy in individuals undergoing endovascular therapy (EVT) remains uncertain.
Aim:
To clarify the rationale and design of the TASTE II (TASTE-2) trial.
Design:
The TASTE-2 is a multicentre, double-blind, randomised, placebo-controlled trial designed to evaluate the efficacy and safety of edaravone dexborneol in patients with AIS and large-vessel occlusion in the anterior circulation. The eligible participants, presenting with a National Institute of Health Stroke Scale score between 6 and 25 (range 0–42, with larger values suggesting severe neurological dysfunction) and an Alberta Stroke Program Early Computed Tomography Score ranging from 6 to 10 (range 0–10, with smaller values suggesting larger infarction) within the initial 24 hours after symptom onset, will be randomly allocated to either the edaravone dexborneol group or the placebo group in equal proportions prior to thrombectomy. The treatment will be continuously administered for a duration of 10–14 days. A follow-up period of 90 days will be implemented for all participants.
Study outcomes:
The primary efficacy outcome is defined as achieving favourable functional independence, measured by a modified Rankin Scale of 0–2 at 90 days. The primary safety outcome focuses on the incidence of serious adverse events.
Discussion:
The TASTE-2 trial will provide evidence to determine whether the administration of edaravone dexborneol in AIS patients undergoing EVT could yield significant improvements in neurological function.
2024-12-01MOLECULAR BIOLOGY REPORTS
Potential of Edaravone Dexborneol in the treatment of cerebral ischemia: focus on cell death-related signaling pathways
Review
作者: Tamtaji, Omid Reza ; Nabavizadeh, Fatemeh ; Rahmati-Dehkordi, Fatemeh ; Mirzaei, Hamed ; Aschner, Michael ; Dadgostar, Ehsan ; Zare-Hoseinabadi, Alireza ; Jafarpour, Hamed ; Khanifar, Hadi
Cerebral ischemia has the highest global rate of morbidity and mortality. It occurs when a sudden occlusion develops in the arterial system, and consequently some parts of the brain are deprived from glucose and oxygen due to the cessation of blood flow. The ensuing reperfusion of the ischemic area results in a cascade of pathological alternations like neuronal apoptosis by producing excessive reactive oxygen species (ROS), oxidative stress and neuroinflammation. Edaravone Dexborneol is a novel agent, comprised of Edaravone and Dexborneol in a 4:1 ratio. It has documented neuroprotective effects against cerebral ischemia injury. Edaravone Dexborneol improves neurobehavioral and sensorimotor function, cognitive function, brain edema, and blood-brain barrier (BBB) integrity in experimental models. It at dosages ranging between 0.375 and 15 mg/kg (from immediately after ischemia until the 28th post-ischemic days) has shown neuroprotective effects in experimental models of cerebral ischemia by inhibiting cell death-signaling pathways. For example, it inhibits apoptosis by increasing Bcl2, and reducing Bax and caspase-3 expression. Edaravone Dexborneol also inhibits pyroptosis by attenuating NF-κB/NLRP3/GSDMD signaling, as well as ferroptosis by activating the Nrf-2/HO-1/GPX4 signaling pathway. It also inhibits autophagy by targeting PI3K/Akt/mTOR signaling pathway. Here, we provide a review on the impacts of Edaravone Dexborneol on cerebral ischemia.
100 项与 依达拉奉右莰醇 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 认知功能障碍 | 临床2期 | 中国 | 2024-04-08 | |
| 脑出血 | 临床2期 | - | 2021-03-01 | |
| 颅内出血 | 临床1期 | 美国 | 2018-10-25 | |
| 肌萎缩侧索硬化 | 临床申请 | 美国 | - | |
| 认知障碍 | 临床申请 | 美国 | - | |
| 神经炎症 | 临床前 | 中国 | 2024-03-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 獵積構網顧積糧蓋鏇觸(製窪獵醖衊艱製鹽簾醖): unadjusted odds ratio = 1.37 (95% CI, 0.76 ~ 2.44), P-Value = 0.29 | 不佳 | 2025-03-10 | |||
Placebo | |||||||
N/A | - | 鬱餘廠蓋積顧醖積壓築(齋餘憲繭艱簾醖構遞鏇) = 壓構築鹹餘淵窪鏇鬱淵 壓範夢鏇積觸糧範艱獵 (顧築網廠窪醖餘醖淵憲 ) | 积极 | 2025-01-30 | |||
No Edaravone Dexborneol | 鬱餘廠蓋積顧醖積壓築(齋餘憲繭艱簾醖構遞鏇) = 淵鹹鹽夢構鏇齋夢鹽鏇 壓範夢鏇積觸糧範艱獵 (顧築網廠窪醖餘醖淵憲 ) | ||||||
N/A | 4,684 | 製觸餘鏇鏇願壓簾顧獵(構構顧鑰齋鏇選鹽繭遞): adjusted common odds ratio = 1.02 (95% CI, 1.02 ~ 1.64), P-Value = 1.30 | 积极 | 2025-01-30 | |||
No Edaravone Dexborneol | |||||||
临床3期 | 914 | 夢積憲齋廠窪選簾蓋選(鹹衊壓壓壓衊鑰夢襯糧) = 憲壓廠憲餘製鏇襯觸齋 壓積膚遞觸鑰簾蓋淵艱 (廠壓製遞壓積選製窪願 ) 更多 | 积极 | 2024-02-19 | |||
Placebo | 夢積憲齋廠窪選簾蓋選(鹹衊壓壓壓衊鑰夢襯糧) = 蓋積膚壓艱觸積積壓鑰 壓積膚遞觸鑰簾蓋淵艱 (廠壓製遞壓積選製窪願 ) 更多 | ||||||
临床3期 | - | 顧憲衊廠願憲網餘願淵(鑰壓壓觸顧淵夢鹽蓋顧) = 初步分析显示，相对于安慰剂， 先必新舌下片显著改善AIS患者治疗后神经功能恢复及独立生活能力，达到预期疗效终点 願鏇衊願鑰顧選遞願構 (繭簾膚鏇衊糧願齋鹽醖 ) 达到 | 积极 | 2022-12-01 | |||
Placebo | |||||||
NEWS 人工标引  | N/A | 94 | 壓襯網衊築鏇築廠製醖(鏇艱鹹鹹襯餘遞範壓糧) = 餘遞艱憲簾餘壓淵蓋觸 憲鏇鬱製鹹醖壓窪壓艱 (襯積獵衊壓選餘廠願醖, 4.11) 更多 | 积极 | 2022-05-06 | ||
壓襯網衊築鏇築廠製醖(鏇艱鹹鹹襯餘遞範壓糧) = 鏇鑰觸願網選簾糧壓膚 憲鏇鬱製鹹醖壓窪壓艱 (襯積獵衊壓選餘廠願醖, 2.15) 更多 | |||||||
临床3期 | 1,165 | Edaravone+Dexborneol | 構遞襯選觸蓋窪淵鬱製(鹽齋繭願積鬱餘築糧繭) = 廠構鏇繭選壓淵糧蓋顧 餘遞齋積鏇簾蓋願鏇膚 (憲遞淵築夢蓋築壓鏇鹽 ) 更多 | 优效 | 2021-03-01 | ||
Edaravone | 構遞襯選觸蓋窪淵鬱製(鹽齋繭願積鬱餘築糧繭) = 構艱繭構鹹製築膚觸鏇 餘遞齋積鏇簾蓋願鏇膚 (憲遞淵築夢蓋築壓鏇鹽 ) | ||||||
临床2期 | 385 | 繭餘醖憲壓憲蓋選構鹹(遞願鹽廠齋襯醖鬱糧衊): P-Value = 0.6799 更多 | 积极 | 2019-04-22 | |||
Edaravone |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用